John Sperzel

Chembio HIV-syphilis test OK’d for Europe, Caribbean

Chembio Diagnostics has been approved to sell its combination test for HIV and syphilis in most of Europe and the Caribbean. The single-use test kits offer rapid detection of antibodies to HIV types 1 and 2 and syphilis Treponema pallidum using whole blood from a finger stick, venous whole blood, serum or plasma. The test requires a tiny blood sample, provides results in as little as 15 minutes and has shelf life of up to 2 years….

International intrigue at Medford’s Chembio

By GREGORY ZELLER // With declining Latin American sales contributing to a revenues losing streak, Chembio Diagnostics has shaken up its international rotation. The Medford-based biotech, which manufactures rapid point-of-care tests for HIV and syphilis, has had its ups and downs, and the latter have largely occurred south of the border. Reporting in March on the 2015 fiscal year, CEO John Sperzel pinned steep revenue and sales drops on a product glut in Mexico and…

Chembio misses on drop in Latin American biz

By GREGORY ZELLER // An oversupplied Latin American market put a dent in Chembio Diagnostic’s 2015 earnings, but coming battles with the Zika virus may turn fortunes around. That was the message to investors Tuesday as CEO John Sperzel III reported the Medford firm’s financials for the year ended Dec. 31, 2015. While the company’s science – point-of-care diagnostic tests for infectious diseases – is in increasing demand, the numbers were not great. Chembio’s reported…